Study guide

8.1 Collaborative Practice Agreements & Medication Therapy Management

Minnesota MPJE Pharmacy Jurisprudence

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the Minnesota MPJE 1.2 NABP Competency Areas & Weights 1.3 How to Use This Guide & Study Strategy

2 Federal Controlled Substances Foundations

2.1 CSA Schedules I–V & MN Alignment 2.2 DEA Registration, Forms 222/106/41 & Security 2.3 Federal CS Prescription Rules (CII–CV) 2.4 Inventories, Recordkeeping & Theft/Loss

3 Federal Drug Regulation, Privacy & Supply Chain

3.1 FD&C Act, Legend vs OTC, Misbranding & Adulteration 3.2 OBRA '90, Medicaid DUR & Federal Counseling Floor 3.3 HIPAA Privacy for Pharmacy 3.4 DSCSA & Drug Supply Chain Integrity

4 MN Board, Licensure & Eligibility

4.1 Minnesota Board of Pharmacy Authority & Sources of Law 4.2 Pharmacist Licensure by Exam & Score Transfer 4.3 License Transfer (Reciprocity) & Background Checks 4.4 Interns, Preceptors & 1,600-Hour Experience

5 Renewal, CE, PIC & Discipline

5.1 License Renewal & 30-Hour Biennial CE 5.2 Pharmacist-in-Charge Duties 5.3 Discipline & Unprofessional Conduct 5.4 HPSP, Impaired Practitioners & Mandatory Reporting

6 Technicians, Interns & Supervision

6.1 Technician Registration, Training & CE 6.2 Supervision Ratios (Statute 151.102 & Rule 6800.3850) 6.3 Intern Scope, Delegation & Certification of Accuracy

7 Prescription Authority & Validity

7.1 Who May Prescribe in Minnesota 7.2 Prescription Content & Validity Requirements 7.3 Controlled Substance Prescribing (Chapter 152 + Federal) 7.4 Refills, Partial Fills & Quantity Limits

8 Advanced MN Pharmacist Practice

8.1 Collaborative Practice Agreements & Medication Therapy Management 8.2 Pharmacist Prescriptive Authority (Minn. Stat. 151.37) 8.3 Immunizations & Vaccine Administration 8.4 Drug Administration & Therapy Management

9 Counseling, DUR & Patient Safety

9.1 Patient Counseling Requirements (Rule 6800.0910) 9.2 Prospective Drug Utilization Review 9.3 Returning & Reusing Drugs (Rule 6800.2700)

10 MN PMP & Opioid Public-Health Laws

10.1 Minnesota PMP Overview, Reporting & Pharmacist Use 10.2 Naloxone Access, Steve’s Law & Opioid Antagonists 10.3 Legitimate Medical Purpose & Red Flags

11 Dispensing: Transfers, Labels & Substitution

11.1 Prescription Transfers Between Pharmacies 11.2 Labeling & Packaging of Dispensed Drugs 11.3 Generic Substitution & Product Selection 11.4 Emergency Dispensing, OTC/BTC & Pseudoephedrine

12 Pharmacy Operations & Facilities

12.1 Pharmacy Permits, Classifications & Inspections 12.2 Security, Delivery & Work Conditions 12.3 Operational Recordkeeping & Inventories 12.4 Central Fill, Centralized Processing & Automation

13 Compounding & Hazardous Drugs

13.1 Sterile, Nonsterile & Hazardous Compounding 13.2 Minnesota Compounding Rules & Beyond-Use Dates

14 Test-Day Strategy & Final Review

14.1 When Minnesota Law Is Stricter Than Federal Law 14.2 Test-Day Strategy & Common Traps

8.1 Collaborative Practice Agreements & Medication Therapy Management

Key Takeaways Explain This Topic AI

Minn. Stat. §151.01, subd. 27 defines the practice of pharmacy to include clinical monitoring, CLIA-waived testing, drug therapy initiation/modification/discontinuation under protocol or collaborative practice agreement (CPA), immunizations, and related advanced services.

A collaborative practice agreement is a written, signed agreement between one or more pharmacists and one or more practitioners authorizing collaborative practice under mutually specified conditions (§151.01, subds. 27b–27c).

Protocol and CPA partners may include dentists, optometrists, physicians, physician assistants, podiatrists, veterinarians, and advanced practice registered nurses authorized to prescribe under §148.235.

Any drug-therapy change made under a protocol or CPA must be documented in the patient’s medical record or reported to a practitioner responsible for the patient’s care.

Medication therapy management–style activities (review, monitoring, adjustment under protocol) sit in NABP Area 2 (Pharmacist Practice, 33%) and are not free-standing independent prescribing of every legend drug.

Last updated: July 2026

8.1 Collaborative Practice Agreements & Medication Therapy Management

Quick Answer: Minnesota embeds advanced clinical pharmacy in Minn. Stat. §151.01, subd. 27 . Pharmacists may initiate, manage, modify, and discontinue drug therapy under a written protocol or collaborative practice agreement (CPA) with authorized practitioners ( clause (7) ). A CPA is a written, signed agreement ( subds. 27b–27c ). Therapy changes must be documented in the medical record or reported to a practitioner responsible for the patient. Separate statutory prescriptive authorities under §151.37, subds. 14–17 (covered in §8.2) do not replace CPA/protocol rules for general drug-therapy management.

NABP Area 2 — Pharmacist Practice (33%) includes administration and therapy management . On the Minnesota MPJE, that means knowing the difference between (1) ordinary dispensing under a prescription, (2) therapy management under a protocol/CPA , and (3) limited pharmacist prescribing under Board protocols in §151.37 . This section builds the protocol/CPA foundation and the broad practice-of-pharmacy map.

Practice of Pharmacy: The Advanced-Care Map

§151.01, subd. 27 is not a marketing slogan—it is the legal inventory of acts that constitute pharmacy practice. High-yield advanced-practice clauses include:

  • Clause theme What statute authorizes (high level)
  • Interpretation / evaluation Evaluate prescription drug orders
  • Compounding / dispensing Compound, label, dispense drugs and devices

Clinical monitoring & CLIA-waived tests Clinical interpretation/monitoring; order/perform CLIA-waived lab tests; collect specimens, interpret/notify, refer; initiate, modify, or discontinue drug therapy only pursuant to protocol or CPA; may delegate test administration to technician or intern under direct pharmacist supervision

Administration & research Drug administration for first dose and medical emergencies; IM/SC administration under a prescription drug order; regimen reviews; drug-related research

Mental-illness IM/SC IM/SC drugs used to treat mental illnesses under order (with post-administration prescriber notice) or under protocol/CPA

Immunizations Initiate, order, administer vaccines under age/ACIP/MIIC rules (detailed in §8.3)

Protocol/CPA therapy management Initiate, manage, modify, discontinue therapy under written protocol or CPA with listed practitioners

Counseling, storage, operations Patient counseling; storage and records; pharmacy management acts

Opioid antagonists (protocol paths) Therapy with opiate antagonists under written protocol or designated public-health protocol paths

§151.37 prescribing hooks Hormonal contraceptives, NRT, acute-overdose opiate antagonists, HIV prevention drugs (and related lab work when requirements met)

Exam reflex: If a vignette says a pharmacist “adjusted warfarin” or “started an ACE inhibitor,” ask: Was there a patient-specific Rx from a practitioner, a protocol/CPA, or a specific §151.37 Board-protocol authority? Minnesota does not give pharmacists general independent authority to prescribe any legend drug for any condition without one of those legal hooks.

Protocol vs Collaborative Practice Agreement

Minnesota defines three related terms carefully:

Protocol (§151.01, subd. 27a)

A protocol is a specific written plan that either:

Describes the nature and scope of activities a pharmacist may engage in when initiating, managing, modifying, or discontinuing drug therapy as allowed in subd. 27, clause (7) ; or

Authorizes a pharmacist to administer vaccines and complies with subd. 27, clause (6) .

Protocols are written and specific . Vague “use your judgment” understandings are not exam-safe answers.

Collaborative practice (§151.01, subd. 27b)

Collaborative practice means patient-care activities, consistent with subd. 27 , engaged in by one or more pharmacists who have agreed to work in collaboration with one or more practitioners to initiate, manage, and modify drug therapy under specified conditions mutually agreed to by the pharmacists and practitioners.

Collaborative practice agreement (§151.01, subd. 27c)

A collaborative practice agreement is a written and signed agreement between one or more pharmacists and one or more practitioners that allows the pharmacist(s) to engage in collaborative practice.

Memorize the formalities: written + signed + mutual conditions . Oral hallway agreements fail the definition.

Who May Be on the Other Side of a Protocol/CPA?

Under subd. 27, clause (7) , therapy initiation/management/modification/discontinuation may proceed according to a written protocol or CPA between:

(i) one or more pharmacists and one or more dentists, optometrists, physicians, physician assistants, podiatrists, or veterinarians ; or

(ii) one or more pharmacists and one or more physician assistants authorized under ch. 147A , or advanced practice registered nurses authorized under §148.235 .

The partner must be a practitioner class the statute recognizes for that collaboration. Do not invent authority to enter a CPA with an unlicensed coach, medical assistant, or out-of-scope professional.

For mental-illness IM/SC administration under clause (5)(ii) , the protocol/CPA partner list again ties to dentists, optometrists, physicians, PAs, podiatrists, veterinarians, or APRNs authorized to prescribe/dispense/administer under §148.235 —and changes must still be documented or reported.

Documentation and Reporting Duties

Statute repeats a bright-line duty for protocol/CPA therapy changes ( clause (7) and parallel language in clause (5)):

Any changes in drug therapy made pursuant to a protocol or collaborative practice agreement must be documented by the pharmacist in the patient’s medical record or reported by the pharmacist to a practitioner responsible for the patient’s care .

MPJE stems often hide this duty in operational detail: the pharmacist adjusts therapy correctly under a CPA but never documents or reports . That is a compliance miss even if the clinical decision was protocol-compliant.

Medication Therapy Management in Minnesota Law Language

“MTM” is common clinical shorthand; the statute speaks in practice-of-pharmacy and protocol/CPA terms. For exam purposes, MTM-style services typically map to:

  • Participation in clinical interpretation and monitoring of drug therapy ( clause (3) )
  • Drug regimen reviews and related selection activities ( clause (4) )
  • Initiation, management, modification, and discontinuation of therapy under protocol/CPA ( clause (7) )

CLIA-waived testing used to support monitoring, with therapy changes still tethered to protocol/CPA when initiating/modifying/discontinuing therapy ( clause (3) )

Patient counseling on therapeutic values, content, hazards, and uses ( clause (9) )—layered with Rule 6800.0910 counseling standards taught elsewhere

CLIA-waived testing trap: A pharmacist may order and perform waived tests and may delegate administration of the test to a technician or intern under direct supervision . That is not freestanding authority to rewrite chronic regimens outside a protocol/CPA. Therapy initiation/modification/discontinuation remains protocol/CPA-bound under clause (3).

How Protocol/CPA Relates to §151.37 Prescribing

Do not collapse frameworks:

Framework Legal hook Scope feel

Protocol / CPA §151.01, subd. 27(7) (+ related clauses) Therapy management with a collaborating practitioner under written plan

Board-protocol prescribing §151.37, subds. 14–17 Specific product categories (contraceptives, NRT, acute-overdose opiate antagonists, HIV prevention) after training + Board standardized protocol

Public-health opiate-antagonist protocols e.g., §151.37, subd. 13 paths; §151.01, subd. 27(11) Expanded access pathways beyond ordinary Rx

§151.37 subdivisions themselves state that nothing in those prescribing authorities prohibits participation in protocol/CPA therapy management under §151.01, subd. 27 . Both can coexist; they answer different legal questions.

Practitioner Definition Cross-Link

§151.01, subd. 23 defines practitioner (physicians, osteopathic physicians licensed to practice medicine, dentists, optometrists, podiatrists, veterinarians, APRNs, certified midwives, PAs, with limited expansions for dental therapists and—for certain sections—pharmacists authorized under §151.37 subds. 14–17). When a CPA refers to “practitioners,” use the statutory definition, not a casual list of “anyone with a white coat.”

Study Checklist

Quote that CPA = written + signed agreement enabling collaborative practice ( 27c ).

List eligible protocol/CPA partners under clause (7) .

State the document or report duty after therapy changes.

Keep CLIA-waived testing separate from freestanding full prescribing.

Distinguish CPA therapy management from §151.37 Board-protocol prescribing.

Map advanced-practice facts to Area 2 study time.

Next: master the four §151.37 pharmacist prescribing lanes—contraception, nicotine replacement, acute-overdose opiate antagonists, and HIV prevention.